MYELODYSPLASTIC SYNDROMES

Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat

Retrieved on: 
Monday, October 25, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Safety, Disease, Health care, Cytopenia, SMC, United Kingdom, National Health Service, Clinical trial, COVID-19, JAK, National Institute, Cytogenetics, RBC, NICE, Quality of life, Diagnosis, Survival, Security (finance), Private Securities Litigation Reform Act, Apoptosis, Frexit, Company, TDP, Acute leukemia, Intellectual property, Iron overload, MAA, Corporation, Innovation, Healthcare Improvement Scotland, MDS, Medication, Fast Track, Marketing, Lymphatic system, Risk, Medicine, Geron Corporation, Chromosome, Microdeletion syndrome, Public health, Nasdaq, MHRA, MF, Heart, Patient, Bone marrow, NHS, Myelodysplastic syndrome, ESA, National Institute for Health and Care Excellence, Pharmaceutical industry, ILAP and Innovation Passport, IMerge Phase 3, Myelodysplastic Syndromes, Imetelstat, Geron, ILAP AND INNOVATION PASSPORT, IMERGE PHASE 3, MYELODYSPLASTIC SYNDROMES, IMETELSTAT, GERON

The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines.

Key Points: 
  • The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines.
  • Imetelstat is currently being studied in two Phase 3 clinical trials, IMerge Phase 3 in lower risk MDS and IMpactMF in refractory myelofibrosis.
  • Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in myeloid hematologic malignancies.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Retrieved on: 
Monday, October 18, 2021
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, General Health, Health, Clinical Trials, Lymphatic system, Patient, ESA, International Prognostic Scoring System, Diagnosis, Bone marrow, Private Securities Litigation Reform Act, Geron Corporation, Nasdaq, Achievement, Heart, Risk, Imetelstat, Microdeletion syndrome, Corporation, Security (finance), MDS, JAK, RBC, Disease, Cytogenetics, Myelodysplastic syndrome, Clinical trial, Acute leukemia, Iron overload, Intellectual property, U.S. Securities and Exchange Commission, Company, Fast Track, Apoptosis, Safety, Chromosome, ESAS, Quality of life, Cytopenia, COVID-19, Pharmaceutical industry, IMerge Phase 3, Myelodysplastic Syndromes, Imetelstat, Geron, IMERGE PHASE 3, MYELODYSPLASTIC SYNDROMES, IMETELSTAT, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
  • Completing patient enrollment in IMerge Phase 3 brings us one step closer to delivering imetelstat as a potential treatment alternative for patients with lower risk MDS who are relapsed or refractory to ESAs.
  • IMerge Phase 3 is a double-blind, randomized, placebo-controlled Phase 3 clinical trial with registrational intent.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.